Abstract 430P
Background
The prognosis of patients with breast cancer brain metastasis (BCBM) remains significantly poor. Accurate prediction of the prognosis of BCBM patients is very important for formulating treatment strategies.
Methods
We retrospectively collected clinicopathological data and MR images per patient diagnosed with BCBM at our center from 2001 to 2021, and validated the updated breast graded prognostic assessment (uB-GPA) in our cohort. Then cox regression analysis was used to identify prognostic clinical factors. Preprocessed MR images and prognostic clinical factors were used together to develop an end-to-end deep learning network based on the transformer encoder in the training set. After feature encoding by the encoder, output sequences were passed to a multi-task logistic regression model to obtain the patients' risk scores. The prognostic performance of the model was evaluated in the test set.
Results
A total of 700 patients with BCBM were enrolled, with a median OS of 11 months (95%CI: 9.8-12.2m). The concordance index (C-index) of uB-GPA was 0.563 (0.551-0.575). Nine clinical factors were shown to be associated with poorer prognosis of patients with BCBM: Age greater than 48 years at BC diagnosis (P=0.003), KPS less than 80 at BCBM diagnosis (P=0.001), triple-negative subtype (P<0.001), initial metastasis site other than the brain (P<0.001), number of brain metastases ≥3 (P<0.001), concurrent leptomeningeal metastasis (P=0.008), not receiving radiotherapy after diagnosis (P=0.003), liver metastasis (P=0.006), and lung metastasis (P=0.049). A deep learning model based on both MR images and clinical factors was developed in the training set (n=166), yielded the C-index of 0.664 and areas under the receiver operative characteristic curve of 0.705, 0.723 and 0.790 respectively for predicting 3-m, 6-m and 12-m OS in the test set (n=36). The median OS of patients in high and low-risk group were 5m (95%CI: 4-9m) and 14m (95%CI: 13m-?), respectively.
Conclusions
This study developed a novel tool to predict survival of patients with BCBM and achieve good performance. It helps in identifying patients' risk of death and in formulating personalized management strategies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
403P - Stemness-targeted therapies to inhibit cancer cell plasticity in triple negative breast cancer
Presenter: Andrew Takchi
Session: Poster session 15
404P - Real-world analysis on molecular targeted therapy recommendations and attainment rates in cancer gene panel testing for metastatic breast cancer
Presenter: Hiroshi Tada
Session: Poster session 15
405P - HRD biomarkers in blood samples from BRCA1/BRCA2-associated advanced breast cancer (BC) patients (pts)
Presenter: Violeta Serra
Session: Poster session 15
406P - Genomic landscape of endocrine therapy (ET)-resistant BRCA1/2 and PALB2 altered metastatic breast cancer (mBC)
Presenter: Abeid Omar
Session: Poster session 15
407P - Genomic profiling and prediction role of the molecular tumor burden index in advanced HR+HER2- breast cancer
Presenter: Xuenan Peng
Session: Poster session 15
408P - Characterizing the genomic landscape of breast cancer in an Irish cohort of patients
Presenter: Georgia Thodi
Session: Poster session 15
409P - Biological tumor traits predicting late recurrence in premenopausal breast cancer patients: Insights from the STO-5 trial with 20-year follow-up
Presenter: Jo De Vos
Session: Poster session 15
410P - Breast cancer lighthouse non-interventional hybrid real-world study: Molecular characterization and 2-year effectiveness data
Presenter: Angela Margarida Nogal Dias
Session: Poster session 15
412P - Exploratory circulating tumor DNA (ctDNA) analysis in HR+/HER2- metastatic breast cancer (mBC) and impact on clinical efficacy with sacituzumab govitecan (SG) in TROPiCS-02
Presenter: Hope Rugo
Session: Poster session 15